comparemela.com
Home
Live Updates
FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer : comparemela.com
FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer
Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.
Related Keywords
Kaplan Meier
,
Rob Iannone
,
Jazz Pharmaceuticals
,
Prescription Drug User Fee Act
,
Lancet Oncology
,
comparemela.com © 2020. All Rights Reserved.